Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The price of Macrogenics Inc (NASDAQ: MGNX) closed at $1.54 in the last session, up 4.76% from day before closing price of $1.47. In other words, the price has increased by $4.76 from its previous closing price. On the day, 0.63 million shares were traded. MGNX stock price reached its highest trading level at $1.58 during the session, while it also had its lowest trading level at $1.47.
Ratios:
We take a closer look at MGNX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.11 and its Current Ratio is at 3.28. In the meantime, Its Debt-to-Equity ratio is 0.47 whereas as Long-Term Debt/Eq ratio is at 0.41.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 15 ’25 when Smith Beth Ann sold 423 shares for $2.56 per share. The transaction valued at 1,083 led to the insider holds 9,532 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MGNX now has a Market Capitalization of 97159056 and an Enterprise Value of -23932226. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.63 while its Price-to-Book (P/B) ratio in mrq is 1.23. Its current Enterprise Value per Revenue stands at -0.155 whereas that against EBITDA is 0.26.
Stock Price History:
The Beta on a monthly basis for MGNX is 1.64, which has changed by -0.7066667 over the last 52 weeks, in comparison to a change of 0.16260707 over the same period for the S&P500. Over the past 52 weeks, MGNX has reached a high of $5.77, while it has fallen to a 52-week low of $0.99. The 50-Day Moving Average of the stock is 4.12%, while the 200-Day Moving Average is calculated to be -37.91%.
Shares Statistics:
According to the various share statistics, MGNX traded on average about 1.21M shares per day over the past 3-months and 667600 shares per day over the past 10 days. A total of 63.09M shares are outstanding, with a floating share count of 57.94M. Insiders hold about 8.16% of the company’s shares, while institutions hold 80.19% stake in the company. Shares short for MGNX as of 1751241600 were 4522294 with a Short Ratio of 3.72, compared to 1748563200 on 6121094. Therefore, it implies a Short% of Shares Outstanding of 4522294 and a Short% of Float of 8.8199995.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The firm’s stock currently is rated by 1.0 analysts. The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.31 and low estimates of -$0.31.
Analysts are recommending an EPS of between -$0.63 and -$0.63 for the fiscal current year, implying an average EPS of -$0.63. EPS for the following year is -$2.66, with 1.0 analysts recommending between -$2.66 and -$2.66.
Revenue Estimates
According to 6 analysts, the current quarter’s revenue is expected to be $28.06M. It ranges from a high estimate of $75.9M to a low estimate of $7.5M. As of the current estimate, Macrogenics Inc’s year-ago sales were $10.8MFor the next quarter, 6 analysts are estimating revenue of $23.31M. There is a high estimate of $48.57M for the next quarter, whereas the lowest estimate is $7.5M.
A total of 6 analysts have provided revenue estimates for MGNX’s current fiscal year. The highest revenue estimate was $151.6M, while the lowest revenue estimate was $30M, resulting in an average revenue estimate of $91.68M. In the same quarter a year ago, actual revenue was $149.96MBased on 5 analysts’ estimates, the company’s revenue will be $91.77M in the next fiscal year. The high estimate is $228.75M and the low estimate is $11M.
